NOXXON Pharma WKN: A3DMC3 ISIN: NL0015000YE1 Kürzel: ALTME Forum: Aktien Thema: Hauptdiskussion

After initial share purchases in May, our CEO continued its share purchases in September. Now owning a position of more than 2,500,000 shares.

Montag eine viel höhere Eröffnung, wenn die Leute diese Nachrichten lesen

endlich wird es wieder entdeckt

das ist mega positiv für die Aktie

steht ein großer Deal bevor?

was weiß er ...

In den letzten Tagen kaufte der CEO jeden Tag

tolle Neuigkeiten!

https://www.tmepharma.com/index.php?option=com_content&view=article&id=67&Itemid=571#Diede-van-den-Ouden-share-purchases

CEO kauft!

https://x.com/tme_pharma/status/1971552295839232152

gogogogo

The Company, under the leadership of its new CEO, Diede van den Ouden, who joined in the June 2025, is currently undertaking a strategic restructuring with the goal of providing the financial resources to unlock the value of NOX-A12 and NOX-E36. Raising funds from alternative sources (€1.7 million raised in May 2025, including €500,000 from the new CEO) Pursuing stable, cash-generating business opportunities to achieve positive operational cash flow for the Company Leveraging tax loss carry forwards Gaining exposure to digital assets via newly established crypto brokerage account

The transition to a virtual model has been smooth—the former team remains available to support us and continues to be motivated to succeed. We are actively engaging in discussions with a broad spectrum of potential partners relating to the Company’s research and development programs and other assets. At the same time, we have reaffirmed our commitment to profitability outside of biotech investments by pursuing the right partnerships, acquisitions, and ventures and other revenue generating initiatives.”

Although we have not yet disclosed concrete news, I am pleased with the progress made during the first three months of my tenure including the aggressive cost-saving measures, which have reduced monthly operating expenses to approximately €100,000 per month, enabling the Company to report a cash balance of €2.35 million at September 1, 2025.

“My share purchases are an indication of my strong belief in the Company’s future, financial position and ability to progress its research and development activities. I expressly reserve the right, when permitted and under appropriate circumstances, to purchase shares in the Company in the market. I am fully aligned with fellow shareholders, having elected only a modest cash remuneration, because the true success of this project rests on the future value of my equity.” said Van den Ouden, CEO.